SIZE XSSIZE SMSIZE MDSIZE LG

Immuno-Oncology: An Overview for Oncology Pharmacists

Immuno-Oncology: An Overview for Oncology Pharmacists was made possible thanks to Educational Grants from AstraZeneca Pharmaceuticals LP and Bristol-Myers Squibb Company

Register Now

Statement of Need/Activity Purpose

Immuno-oncology and immunotherapy have rapidly become one of the most promising new fields for cancer treatment. The rapidly growing use of immunotherapy agents to treat cancer can present a challenge for oncology healthcare professionals, including the oncology pharmacists that help prescribe, monitor, and counsel the patients on the use of these immunotherapy agents. It is also important that oncology pharmacists are well versed on the identification and treatment of immune related adverse effects associated with these therapies. Immuno-oncology, an Overview for Oncology Pharmacists Educational Modules will address the needs of immuno-oncology education through a review of how the immune system and cancer interact, reviewing the mechanism and activity of immunotherapy agents, reviewing appropriate clinical guidelines for the management of immune related adverse events, and discussing recent FDA approvals of immunotherapy agents and new drugs in the pipeline. This comprehensive overview of immuno-oncology will prepare the oncology pharmacist for managing patients with these therapies.

Faculty

jennifer swank

Jennifer Swank, PharmD BCOP
Medical Oncology Clinical Pharmacist
Moffitt Cancer Center

Jennifer Swank, PharmD BCOP, is a Clinical Pharmacist at the H. Lee Moffitt Cancer Center and PGY-2 Oncology Specialty Pharmacy residency director. She is also an Assistant Professor at University of Florida and University of South Florida pharmacy schools. Her primary role is working in direct patient care as an inpatient clinical pharmacist in Medical Oncology.

Dr. Swank received her Doctor of Pharmacy Degree from Butler University. She completed her PGY1 Pharmacy Practice Residency at the James A Haley VA Indianapolis and PGY2 Oncology Pharmacy Residency at Moffitt Cancer Center. She has been a Board Certified Oncology Pharmacist since 2007 and has been practicing in her current role for over 13 years. Dr. Swank has been involved in direct patient care for the immunotherapy patient population and worked with a multidisciplinary group of practitioners to create institution wide guidelines for the management of immunotherapy-related adverse effects.

Disclosures:

None

Module 1: Introduction and Overview to Immuno-Oncology

General introduction to the immune system and its interaction with cancer. This module will cover the pharmacology and therapeutic use of immunotherapy and adoptive cell therapy including checkpoint inhibitors, TCR, and CAR-T cell therapy. Discussion on PDL-1 testing and application to treatment with checkpoint inhibitors is also discussed

Learning Objectives

After completing this module learners should be able to . . .

  • Outline the mechanism of action of immunotherapy-related adverse effects (irAE)
  • Review the multidisciplinary NCCN and ASCO guidelines for the identification and management of irAE
  • Apply guideline driven management irAE management to patient care
  • Understand and apply patient education principles in daily practice
  • Outline the mechanism of active of cytokine release syndrome (CRS) and CAR-T cell related encephalopathy syndrome (CRES) from CAR-T therapy
  • Recommend strategies for CRS and CRES management from CAR-T therapy

 

Module 2: Management of Immunotherapy Related Adverse Effects (irAE)

Discuss the pathophysiology and management of irAE. Comprehensive review and patient case centered learning model of the NCCN guidelines, ASCO guidelines, and ASBMT guidelines for the treatment of irAE from checkpoint inhibitor therapy and CRS and CRES management from CAR-T cell therapy. Also provides guidelines for interaction and discussion with patients regarding these toxicities.

Learning Objectives

After completing this module learners should be able to . . .

  • Outline the mechanism of action of immunotherapy-related adverse effects (irAE)
  • Review the multidisciplinary NCCN and ASCO guidelines for the identification and management of irAE
  • Apply guideline driven management irAE management to patient care
  • Understand and apply patient education principles in daily practice
  • Outline the mechanism of active of cytokine release syndrome (CRS) and CAR-T cell related encephalopathy syndrome (CRES) from CAR-T therapy
  • Recommend strategies for CRS and CRES management from CAR-T therapy

 

Module 3: Immuno-Oncology Updates

Review of the FDA immunotherapy approvals since January of 2018. Discuss potential new immunotherapy agents in the pipeline for FDA approval

Learning Objectives

After completing this module learners should be able to . . .

  • Outline the mechanism of action of immunotherapy-related adverse effects (irAE)
  • Review the multidisciplinary NCCN and ASCO guidelines for the identification and management of irAE
  • Apply guideline driven management irAE management to patient care
  • Understand and apply patient education principles in daily practice
  • Outline the mechanism of active of cytokine release syndrome (CRS) and CAR-T cell related encephalopathy syndrome (CRES) from CAR-T therapy
  • Recommend strategies for CRS and CRES management from CAR-T therapy

 

Target Audience

This activity is intended for Hematology/Oncology pharmacists. This activity has been approved for 3.0 contact hours (.30CEUs) under the ACPE universal activity number # 0465-0000-19-061-H04-P.

Activity Type:

Knowledge

Registration Fees:

HOPA Member ‒ $0

Accreditation Statement:

logo acpeThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. A statement of credit will be issued only upon completion of the post-activity evaluation form and post-test.

If you have questions about these modules, please contact HOPA's Education Support at This email address is being protected from spambots. You need JavaScript enabled to view it..

 

 

xs
sm
md
lg